Limitations and Remaining Questions While semaglutide has shown significant benefits in reducing joint pain among patients with obesity, several important limitations remain: Studies often lack post-treatment follow-up, making it unclear how durable these pain and weight outcomes are once medication is stopped
Spread protein intake across three to four meals rather than loading it into one sitting, because the body can only utilize about 25-40 grams of protein per meal for muscle and tissue synthesis
If youre on medications that affect copper status (ex
Listening to Your Body The most important thing you can do during pregnancy is listen to your intuition and your body's signals
The recognition of a role for GLP-1 in the pathophysiology of congenital and acquired hyperinsulinemic hypoglycemia has brought forward the possibility of targeting the GLP-1 receptor for the treatment of this condition and promising progress has been made to this end
Studies have shown that the incidence of vomiting with dulaglutide (a GLP-1RA) was reported at 17%, compared to 12% with exenatide, indicating variability among different GLP-1 agonists